Epstein-Barr virus (EBV) latently infected B-cells are the precursors of EBV-associated malignancies. EBV-infection induces the production of pro-survival and anti-inflammatory cytokines that may be important in the transition between latency and malignancy. One EBV protein, LMP2A, can be detected in both latently infected resting B-cells and in EBV-associated malignancies. Therefore, we tested the ability of LMP2A to influence cytokine production using both LMP2A-Tg primary B-cells and LMP2A-expressing B-cell lines. Our data demonstrate that LMP2A does not globally alter B-cell-produced cytokine levels, but specifically targets IL-10. Additional studies using ELISA and real-time-RT-PCR confirm that LMP2A utilizes PI3-kinase to increase IL-10 levels. Finally, the data demonstrate that LMP2A-expressing B-cell lines are more dependent on IL-10 for survival in comparison to LMP2A-negative B-cell lines. These data identify a novel function of LMP2A in the alteration of a cytokine that is important for both tumour survival and anti-tumour responses.
Epstein-Barr virus (EBV) maintains a latent state with the expression of very few proteins in memory B-cells and EBVassociated lymphomas. The EBV protein, latent membrane protein 2A (LMP2A), can be detected in both latent and pathological states (Decker et al. 1996; Niedobitek et al. 1997; Babcock et al. 1998 Babcock et al. , 2000 Babcock et al. , 2001 Hochberg et al. 2004; Bell et al. 2006) . The expression of LMP2A at multiple stages of EBV infection suggests that LMP2A plays an important role in both EBV latency and EBV-associated pathology. Previous studies demonstrate that LMP2A promotes B-cell survival in resting B-cells and pre-tumour B-cells through increases in Bcl family members (Bechtel et al. 2005; Mancao & Hammerschmidt 2007; Bultema et al. 2009; SwansonMungerson et al. 2010) . The survival of B-cells and B-cell lymphomas is also regulated in part by cytokines (Banchereau et al. 1993; Brennan, 2001) and it is underappreciated that B-cells are capable of producing cytokines to promote their own survival and proliferation in an autocrine manner (O'Garra & Vieira, 2007) . Previous studies indicate that EBV infection modulates B-cell cytokine production (Samanta et al., 2008; Konforte & Paige, 2009; Tsai et al., 2009) . However, to date there is no published data testing the possibility that LMP2A directly regulates B-cell cytokine production to modulate B-cell proliferation, survival, lymphoma generation, and/or pathology. Therefore, we initially tested if LMP2A influences cytokine production using B-cells from LMP2A-Tg mice (Caldwell et al., 1998) . Lipopolysaccharide (LPS) or an activating anti-CD40 mAb was used in these experiments, since both stimuli induce cytokine production by B-cells (O'Garra et al., 1990; O'Garra & Howard, 1992; Burdin et al., 1995) . Purified CD19 + B-cells from both non-transgenic (non-Tg) and LMP2A-Tg mice were stimulated with either LPS or anti-CD40 mAb to induce cytokine production for 48 h and supernatants were analysed using a mouse ELISArray (SA Biosciences). The results suggest that LMP2A does not globally influence B-cell cytokine production (Table S1 , available in JGV Online), but rather, that LMP2A increases IL-10 production approximately twofold in response to both LPS-and CD40-stimulation. The finding that IL-10 is specifically enhanced by LMP2A is intriguing due to the role of IL-10 in both dampening antiviral immune responses and promoting the survival of B-cell lymphomas (Cortes & Kurzrock, 1997) . To confirm that LMP2A increases mitogen-induced IL-10 production using the LMP2A-Tg mouse model, purified non-Tg and LMP2A-Tg B-cells were cultured in the absence or presence of either LPS or anti-CD40 mAb and IL-10 levels were determined by either ELISA or quantitative real-time-RT-PCR. These data confirm that LMP2A-Tg B-cells produce more IL-10 protein (Fig. 1a) and RNA (Fig. 1b ) in response to LPS or anti-CD40 mAb when compared with non-Tg B-cells.
Previous studies indicate that LPS increases the proliferation of LMP2A-Tg B-cells (Ikeda et al., 2004) . Thus, the LMP2A-dependent increase in IL-10 in Fig. 1(a) could be due to the fact that the LMP2A-Tg B-cells are hyperproliferative to LPS, resulting in more B-cells present to produce IL-10. To rule out this interpretation, we tested if LMP2A increases the amount of IL-10 made per B-cell after LPS exposure by flow cytometry. When intracellular IL-10 levels are assessed, LMP2A-Tg B-cells demonstrate a significantly higher mean fluorescence intensity than non-Tg B-cells (Fig. 1c) , indicating that LMP2A-Tg B-cells produce more IL-10 per cell. Taken together, these data indicate that LMP2A directly increases IL-10 production in mitogen-stimulated primary B-cells.
Since LMP2A is also identified in EBV-associated tumours (Niedobitek et al., 1997; Bell et al., 2006) , we sought to determine if LMP2A increases IL-10 production in human B-cell lymphomas. Since our transgenic B-cells required stimulation to induce cytokine production, we tested if LMP2A affects LPS-induced cytokine production, including IL-10, in a human B-cell lymphoma. For these studies, we used an established LMP2A-expressing BJAB cell line (BJAB-LMP2A.1) and the control cell line that contains only the vector (BJAB-Vector.1) (Miller et al., 1993) . In a manner similar to LMP2A-Tg B-cells, LMP2A does not + B-cells were isolated and cultured as above before RNA isolation, followed by equal amounts of RNA used for reverse transcription (qScript cDNA Supermix; Quanta BioSciences) according to manufacturer's instructions. cDNA was amplified using murine-specific IL-10 or GAPDH primers as previously described (de Waal Malefyt et al., 1991; Enk & Katz, 1992 ) with a SybrGreen PCR master mix. Relative gene expression was determined by the DDC t method, and results are expressed as the fold-increase above levels detected in LPS-or CD40-stimulated non-Tg B-cells. (c) Non-Tg and LMP2A-Tg B-cells were cultured as described above with Golgi-stop (BD Biosciences) added for the final 4 h. Intracellular IL-10 staining was performed as suggested by the manufacturer (BD Biosciences), followed by flow cytometric analysis on a FACSCalibur instrument. BLD, Below the level of detection. The data represent three experiments with similar results. All error bars are indicative of SEM. An asterisk (*) indicates a P-value of ,0.05 using a two-tailed t-test when compared to non-Tg B-cells stimulated with the same mitogen.
modulate any LPS-induced cytokines, except for LPSinduced IL-10 (Table S1 ). Subsequent experiments confirm that LMP2A increases LPS-induced IL-10 at both the protein and RNA level (data not shown). Additionally, we tested if LMP2A increases basal cytokine production in LMP2A-expressing B-cell lines. BJAB-Vector.1 and BJAB-LMP2A.1 cells were incubated for 48 h in the absence of any stimuli and supernatants were analysed by ELISArray. As shown in Table S1 , LMP2A enhances basal IL-10 production in unstimulated BJAB cells. Subsequent experiments using both ELISA and quantitative RT-PCR demonstrate that LMP2A increases basal IL-10 levels at both the protein (Fig.  2a ) and RNA levels (Fig. 2c) . To confirm that the LMP2A-mediated increase in IL-10 is not specific to BJAB cells, similar experiments were performed using an LMP2A-expressing Ramos cell line (Fukuda & Longnecker, 2004) . Fig. 1 (b) using primers specific for human IL-10 and GAPDH. The results are expressed as fold-increase above levels detected in cell lines lacking LMP2A. (e) LCL1, BJAB or Ramos cell lines were stained for LMP2A as described previously (Ikeda & Longnecker, 2007) with either anti-rat IgG-TRITC alone (26 only) or anti-LMP2A (clone 114B7; generously provided by Richard Longnecker) followed by anti-rat IgG-TRITC (anti-LMP2A Ab; Biolegend). The data represent two to three experiments with similar results. All error bars are indicative of SEM. An asterisk (*) indicates a P-value of ,0.05 using a two-tailed t-test when compared to control cells lacking LMP2A.
LMP2A utilizes PI3K to increase IL-10 LMP2A again increased basal levels of IL-10 at both the protein (Fig. 2b ) and RNA levels (Fig. 2d ) in the Ramos cell line. Taken together, these data confirm that LMP2A increases basal IL-10 levels in B-cell lymphomas.
To rule out the possibility that the cell lines used in Fig. 2 express significantly higher LMP2A levels than those found naturally after EBV transformation, as in a lymphoblastoid cell line (LCL), we compared LMP2A levels by immunofluorescence and did not see any significant difference between the LCL, LCL1 (Ikeda & Longnecker, 2007) , the BJAB-LMP2A.1 cells or the Ramos-LMP2A cells (Fig. 2e) .
Additionally, the ELISArray implicated that LMP2A increases TGF-b production in unstimulated BJAB-LMP2A.1 B-cells (Table S1 ). However, these findings were not confirmed in later experiments (data not shown). The fact that LMP2A did not increase the levels of TGF-b suggest that LMP2A is not driving the differentiation of these B-cells to a IL-10 + TGF-b + 'regulatory B-cell' phenotype (Mizoguchi & Bhan, 2006) . IL-10 is a cytokine with pleotropic effects on the immune system. IL-10 not only dampens cellular immune responses in the environment of tumours, but also enhances the survival and proliferation of B-cell tumours in vivo (Beatty et al., 1997; Cortes & Kurzrock, 1997; Khatri & Caligiuri, 1998; Vockerodt et al., 2001) . We initially assessed if LMP2A increases proliferation of the BJAB cell line. As shown in Fig. 3(a) , our data indicate that the level of proliferation in BJAB-LMP2A.1 cells is equivalent to the level of proliferation in BJAB-Vector.1 cells. These findings are consistent with previous studies, indicating that LMP2A does not significantly affect the proliferation of transformed B-cells in vitro and in vivo (Longnecker et al., 1992; Rochford et al., 1997 ). Therefore, we tested the possibility that the increase in basal IL-10 levels in BJAB-LMP2A.1 cells significantly enhances the survival of these cells. BJAB-Vector.1 and BJAB-LMP2A.1 cells were incubated in the presence of a neutralizing IL-10 antibody or isotype control antibody for 24 h and the percentage of apoptotic cells was determined by Annexin-V staining.
LMP2A-expressing cells demonstrate a significant decrease in the percentage of cells that are Annexin-V-positive (Fig.  3b-c) , suggesting that LMP2A increases the survival of these cells. However, the addition of a neutralizing IL-10 antibody to BJAB-LMP2A.1 cells increases the percentage of Annexin-V-positive cells to levels found in BJABVector.1 cells (Fig. 3b-c) , suggesting that the LMP2A-mediated increase in IL-10 is important for promoting the survival of these cells.
It initially is surprising that the LMP2A-mediated increase in survival did not translate to increases in the number of cells in Fig. 3(a) . However, the percentage of Annexin-Vpositive cells are low in our assay: therefore, the decrease in Annexin-V-positive cells probably does not translate into differences in the overall number of cells detected by our proliferation assay at 48 h. However, it is likely that an LMP2A
+ tumour in vivo expressing IL-10 would have a significant advantage by promoting its own survival and dampening anti-tumour immune responses.
IL-10 production in B-cells is modulated by numerous signal transduction pathways, including PI3-kinase (PI3K) (Lambert & Martinez, 2007; O'Garra & Vieira, 2007) . LMP2A constitutively activates the Ras/PI3K pathway (Portis & Longnecker, 2004) and therefore, experiments were designed to analyse if LMP2A utilizes PI3K to modulate basal levels of IL-10 production. The addition of the PI3K inhibitor, LY294002, significantly decreases IL-10 protein levels in both the BJAB-LMP2A.1 and Ramos-LMP2A cell lines (Fig. 3d-e) , suggesting that LMP2A requires the activation of PI3K to augment the basal levels of IL-10.
While the PI3K inhibitor decreases IL-10 production in the BJAB-LMP2A.1 cells at both the protein and RNA levels (Fig. 3d, f) , the PI3K inhibitor only slightly inhibits IL-10 protein ( Fig. 3d) and not IL-10 RNA (Fig. 3f ) in the BJABVector.1 cells. IL-10 is regulated at both the transcriptional and post-transcriptional levels (Saraiva & O'Garra, 2010) and there is a paucity of data analysing the regulatory mechanisms responsible for influencing IL-10 production in B-lymphocytes. Our data point to the possibility that LMP2A regulates IL-10 production in a distinct manner from IL-10 regulation in transformed B-cells that lack LMP2A. If this is the case, it is possible that drugs directed at novel regulatory mechanisms employed by LMP2A may help target LMP2A-positive, IL-10-producing tumour cells, such as lymphoma cells from post-transplant lymphoproliferative disease (PTLD).
The data presented here may have important clinical relevance, since a recent finding highlights the importance of IL-10 in EBV-positive cell lines derived from PTLD patients (Hatton et al., 2011) . This report demonstrates that the addition of a Syk inhibitor to PTLD cell lines leads to a decrease in IL-10 levels and the apoptosis of PTLD cells (Hatton et al., 2011) . Furthermore, the data demonstrate that Syk directly increases PI3K levels that are important for PTLD cell survival (Hatton et al., 2011) . The authors of this study infer that the addition of the Syk inhibitor directly acts on LMP2A signalling and that LMP2A is responsible for increases in IL-10 production in the PTLD cell lines. However, the data in this report are the first to demonstrate that LMP2A directly increases IL-10 (Figs 1 and 2 ) to promote the survival of B-cell lymphoma lines (Fig. 3) .
Since IL-10 promotes the survival of EBV-associated tumours, these data provide an exciting new potential mechanism by which EBV may promote tumour development and survival. It is interesting to note that IL-10 appears to be extremely important throughout EBV infection. During initial infection, EBV expresses the gene BCRF-1 that encodes an EBV viral homologue of human IL-10 (Rode et al., 1994) . EBV vIL-10 has a much lower affinity for the IL-10R (Yoon et al., 2012) ) cells were incubated in the presence of 1 mg ml "1 of a neutralizing anti-human IL-10 mAb (clone JES3-9D7) or an isotype control (rat IgG1; Biolegend). After 24 h, the cells were stained with Annexin-V (Biolegend) and analysed on a FACSCalibur. The data in (a) and (c) are a combination of three experiments. (d-f) BJAB or Ramos cells were incubated as described in Fig. 2 in the absence or presence of LY294002 (10 mM) for 48 h. ELISA (d-e) and real-time-RT-PCR (f) were performed as described in Fig. 2 . The data in (d-f) represent two to three experiments with similar results. All error bars are indicative of SEM. An asterisk (*) indicates a Pvalue of ,0.05 using a two-tailed t-test when compared to control cells lacking LMP2A. A double asterisk (**) indicates a P-value of ,0.05 using a two-tailed t-test when compared to cells not exposed to a neutralizing antibody (c) or PI3K inhibitor (d-f).
LMP2A utilizes PI3K to increase IL-10 et al., 1997; Yoon et al., 2012) and to protect infected B-cells from immune recognition (Jochum et al., 2012) . However, since both LMP2A and another EBV latency protein, LMP1, increase IL-10 production (Lambert & Martinez, 2007) , it suggests that EBV continues to modulate IL-10 production during latency to protect EBV-infected B-cells from immune recognition and promote B-cell survival. This redundancy implies that the modulation of IL-10 could be a critical function of EBV latency proteins in the generation and maintenance of EBV-associated tumours. Future studies that identify downstream targets of LMP2A that are responsible for increasing IL-10 may elucidate potential new therapies against EBV-associated diseases.
